Status:
COMPLETED
Sedation With Remimazolam During Spinal Anesthesia
Lead Sponsor:
Gangnam Severance Hospital
Conditions:
Sedation
Spinal Anesthesia
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
Remimazolam is a benzodiazepine-binding site antagonist of the GABA receptor, metabolized by esterases, and exhibits a stable context-sensitive half-life of 6-7 minutes. Remimazolam has a high clearan...
Eligibility Criteria
Inclusion
- Severe cardiovascular or respiratory disease
- Contraindication to spinal anesthesia
- Heart block
- Previous hepatectomy or liver transplant
- Patients with moderate or more hepatic impairment (AST/ALT is more than 2.5 times the upper limit of normal)
- Estimated glomerular filtration rate \< 30 mL/min/1.73m2
- Acute narrow angle glaucoma
- Myasthesia gravis
- Known allergy to the drugs included in the study
Exclusion
- Patients 19 years of age or older who are expected to elective orthopedic surgery under spinal anaesthesia
- ASA PS 1-3
Key Trial Info
Start Date :
April 19 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 15 2022
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT05305248
Start Date
April 19 2022
End Date
September 15 2022
Last Update
May 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gangnam Severance Hospital
Seoul, South Korea